VBLT News and Press, Vascular Biogenics Ltd. From 03/08/22

Phase 3 OVAL trial enrolled 409 patients globally at centers in the United States, Europe, Israel, and Japan Top-line data from progression free survival (PFS) primary endpoint expected in 2H 2022 expected to have the potential to support a Biologics License Application (BLA) subm...

TEL AVIV, Israel and NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today an...

TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the...

TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dro...

CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expect...

TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory indications, today announced that Dror Harats...

VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL AVIV, Israel and NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics ...

Vascular Biogenics Ltd. (VBLT) Q3 2021 Earnings Conference Call November 15, 2021 08:30 AM ET Company Participants Dror Harats - Chief Executive Officer Sam Backenroth - Chief Financial Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Swayampakula Ramakanth - H.C. Wainwright ...

VBL Therapeutics (NASDAQ:VBLT): Q3 GAAP EPS of -$0.09 beats by $0.01. Revenue of $0.2M (+5.3% Y/Y) beats by $0.07M. Press Release At September 30, 2021, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $50.8M. VBL expects that its cash, cash equivalents...

Conference Call and Webcast at 8:30 a.m. ET Today Data from multiple VB-111 clinical trials expected in 2022, including the progression free survival (PFS) co-primary endpoint from the Phase 3 OVAL study expected in the second half of 2022 More than 85% of the plan...